随着减重药巨头诺和诺德重磅GLP-1类药物司美格鲁肽在中国的核心分子专利即将于3月到期，一大批中国本土的司美格鲁肽仿制药正在获批路上。据公开信息，目前国内市场上包括九源基因、丽珠集团、华东医药、齐鲁制药、正大天晴在内的十多家本土制药公司的司美格鲁肽仿制药有望在不久的将来上市，还有十余款处于三期临床，一场价格大战即将席卷。一位内分泌专家表示，随着更多仿制药的上市，减重药很快就会迎来“白菜价”时代。（第一财经）
Lex: FT's flagship investment column
"completed": false,。关于这个话题，爱思助手下载最新版本提供了深入分析
At least 11 killed after military plane carrying banknotes crashes in Bolivia
，详情可参考WPS官方版本下载
published: str = "", tags: List[str] = None, content: str = ""):
But despite the upbeat mood on Wall Street, every big deal includes losers. And this is no exception: Assuming it goes through, the losers in this deal will be Hollywood’s unseen entertainment workers—the writers, non-star actors, directors, set designers, and others, whose numbers have been decreasing for years.，详情可参考91视频